"Raynaud phenomenon: from GWAS to drug repurposing" - 2024
"The identification of novel risk variants in the largest genome-wide association study of Raynaud phenomenon to date provides insights into the pathophysiology of the condition, including the potential role for α2A-adrenoceptors, and suggests opportunities for drug repurposing."
Our hope is that the DecodeME will get us closer to that goal -
Couldn't get access to full paper - https://www.nature.com/articles/s41...w GWAS included 5,147,: ADRA2A, IRX1 and MICB.
"The identification of novel risk variants in the largest genome-wide association study of Raynaud phenomenon to date provides insights into the pathophysiology of the condition, including the potential role for α2A-adrenoceptors, and suggests opportunities for drug repurposing."
Our hope is that the DecodeME will get us closer to that goal -
Couldn't get access to full paper - https://www.nature.com/articles/s41...w GWAS included 5,147,: ADRA2A, IRX1 and MICB.
